Son receptivos, atentos y sumamente serviciales
FDA approval for a new indication for Wegovy (semaglutide) to reduce the risk of major adverse cardiovascular events, including cardiovascular death, heart attack, and stroke, in adults with cardiovascular disease and obesity or overweight
As of now, GLP-1-related triple agonists are primarily still in the development stage and have not been widely approved for use
Commercial plans are far more likely to cover Ozempic , even with prior authorization , than Wegovy, because diabetes drugs fall under essential health benefits in a way that obesity drugs do not
6466 These agents improved glucose tolerance, reduced food intake, and promoted weight loss
The combination of effects has led to significant sustained weight loss, improvements in metabolic markers, and, often, a positive impact on other comorbid chronic disease states